Tag: <span>micelle nanoparticle</span>

Rapid Manufacture and Release of a GMP Batch of Zaire Ebolavirus Glycoprotein Vaccine Made Using Recombinant Baculovirus-Sf9 Insect Cell Culture Technology

For the ongoing 2014 Ebola virus outbreak, all viable options and technologies need to be evaluated as potential countermeasures to address this emerging biological threat. Novavax, Inc. has a rapid, practical vaccine development and manufacturing platform with the capability to deliver clinical trial material and, ultimately, commercial doses in response to novel infectious disease agents. This report describes the application of our platform technology for the successful generation, manufacture, and release of a clinical batch of Zaire ebolavirus glycoprotein nanoparticle vaccine three months from project initiation…

Read MoreRapid Manufacture and Release of a GMP Batch of Zaire Ebolavirus Glycoprotein Vaccine Made Using Recombinant Baculovirus-Sf9 Insect Cell Culture Technology

Baculovirus Expression Technology Biologics Biologics Production Cell Lines Manufacturing Quality Risk Management (QRM) Regulatory Vaccines

ebolavirus vaccine glycoprotein glycoprotein vaccine gp2 micelle nanoparticle nanoparticle vaccine sf9 baculovirus Spodoptera frugiperda Zaire ebolavirus